Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Bullish +60

Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now - 24/7 Wall St.

📉 Moderna's full-year 2025 revenue collapsed to $1.94 billion, representing a roughly 40% drop from the prior year.

💸 Moderna's year-end cash is projected to fall from $8.1 billion at the end of 2025 to between $4.5 billion and $5.0 billion by year-end 2026.

📈 Gilead Sciences generated Q1 2026 HIV franchise revenue of $5.03 billion, a 10% increase driven by Biktarvy sales of $3.36 billion.

💰 Gilead declared a quarterly dividend of $0.82 payable June 29, 2026, and repurchased $419 million of stock in Q1 alone.

🔬 Moderna's upcoming catalysts are binary events like the August 5, 2026 flu vaccine PDUFA rather than steady earnings drivers.

🛡️ Gilead's patent protection on Biktarvy was extended to April 2036, ensuring no major loss of exclusivity for a full decade.

📊 Gilead trades at a forward earnings multiple of 15 with a market cap near $162 billion compared to Moderna's depressed base.

🧬 Gilead's headline EPS loss guidance is an artifact of roughly $11.5 billion in one-time IPR&D charges from acquisitions like Arcellx and Ouro Medicines.

Bullish Signals
  • Gilead Sciences is generating real free cash flow, with Q1 free cash flow hitting $2.427 billion, up 237.08% year over year.
  • Gilead's HIV franchise grew 10% to $5.03 billion in Q1 2026, demonstrating strong recurring revenue potential.
  • Gilead offers tangible shareholder returns via a 2.46% dividend yield and a $6.0 billion buyback authorization.
  • Gilead's non-GAAP product gross margin expanded 200 basis points to 87.5%, indicating operational efficiency.
  • Gilead possesses a strong pipeline with up to four potential launches and five Phase 3 updates anticipated in 2026.
  • Moderna's recent stock surge is attributed to a prior year disaster rather than improved fundamentals, suggesting the bounce may be temporary.
Risk Factors
  • Moderna's entire franchise is effectively a single COVID product, creating concentration risk outside the U.S. market.
  • Moderna has no dividend and no buyback program while actively drawing on its credit facility to manage liquidity.
  • Moderna's upcoming catalysts are binary events with high uncertainty rather than predictable earnings drivers.
  • Gilead's headline EPS loss guidance is driven by roughly $11.5 billion in one-time IPR&D charges from acquisitions, which may impact reported profitability.
Full Analysis
The article argues that while Moderna (MRNA) recently surged 63% year-to-date following a Q1 revenue triple, its long-term fundamentals remain weak. Full-year 2025 revenue collapsed to $1.94 billion, a roughly 40% drop, with management projecting only up to 10% growth for 2026 off this depressed base. Approximately 80% of Q1 2026 sales originated outside the U.S., and the company's franchise is still heavily reliant on a single COVID product. Moderna faces significant financial headwinds, with year-end cash projected to fall from $8.1 billion at the end of 2025 to between $4.5 billion and $5.0 billion by the end of 2026. The company drew $600 million on a credit facility while Q1 GAAP net loss widened to $1.34 billion. There are no dividends or buybacks, and upcoming catalysts like the August 5, 2026 flu vaccine PDUFA and melanoma readouts are described as binary events rather than steady earnings drivers. In contrast, the author recommends Gilead Sciences (GILD) as a superior long-term holding for retirement portfolios. Gilead is characterized as a cash-flow machine with an HIV franchise that grew 10% to $5.03 billion in Q1 2026, driven largely by Biktarvy which generated $3.36 billion alone. The company trades at a forward earnings multiple of 15 and offers a 2.46% dividend yield with a market cap near $162 billion. Gilead provides real shareholder returns through a declared quarterly dividend payable June 29, 2026, and significant stock repurchases totaling $419 million in Q1 alone against a $6.0 billion buyback authorization. The company's headline EPS loss is attributed to roughly $11.5 billion in one-time IPR&D charges from recent acquisitions rather than operational issues. With a strong pipeline including four potential launches and five Phase 3 updates anticipated in 2026, Gilead can fund its growth from operating cash flow.